Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -24.68% is 50% above its 5-year average of -49.36%, near the high end of its 5-year range (-469.82%–0.00%).
6.10% above its 12-month average of -26.28%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -23.50%.
NET PROFIT MARGIN
-24.68%
NET PROFIT MARGIN AVG TTM
-26.28%
NET PROFIT MARGIN AVG 3Y
-67.43%
NET PROFIT MARGIN AVG 5Y
-49.36%
NET PROFIT MARGIN AVG 10Y
-16.85%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.10%
CURRENT VS 3Y AVG
+63.40%
CURRENT VS 5Y AVG
+50.00%
CURRENT VS 10Y AVG
-46.44%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 691 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Axsome Therapeutics, Inc.
Market Cap
$8.99B
Net Profit Margin
-24.68%
TTM Avg
-26.28%
3Y Avg
-67.43%
5Y Avg
-49.36%
Market Cap
$8.98B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
Market Cap
$9.00B
Net Profit Margin
29.40%
TTM Avg
-109.74%
3Y Avg
-207.58%
5Y Avg
-253.39%
Market Cap
$8.80B
Net Profit Margin
-47.79%
TTM Avg
-8441.28%
3Y Avg
-4260.06%
5Y Avg
-2873.03%
Market Cap
$9.30B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
Market Cap
$8.75B
Net Profit Margin
-285.41%
TTM Avg
-634.98%
3Y Avg
-446.89%
5Y Avg
-343.19%
Market Cap
$8.44B
Net Profit Margin
3.60%
TTM Avg
-1.75%
3Y Avg
-5.71%
5Y Avg
-20.27%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $8.99B | -24.68% | -26.28% | -67.43% | -49.36% |
| Bruker Corporation (BRKRP)vs › | $8.98B | -2.03% | 1.55% | 7.31% | 8.11% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $9.00B | 29.40% | -109.74% | -207.58% | -253.39% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.80B | -47.79% | -8441.28% | -4260.06% | -2873.03% |
| Bruker Corporation (BRKR)vs › | $9.30B | -2.03% | 1.55% | 7.31% | 8.11% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.75B | -285.41% | -634.98% | -446.89% | -343.19% |
| Insulet Corp. (PODD)vs › | $9.40B | 12.29% | 14.66% | 10.46% | 7.35% |
| Oscar Health, Inc. (OSCR)vs › | $8.44B | 3.60% | -1.75% | -5.71% | -20.27% |
| Vaxcyte, Inc. (PCVX)vs › | $9.70B | 0.00% | 0.00% | 0.00% | 0.00% |
| Henry Schein, Inc. (HSIC)vs › | $9.74B | 2.96% | 3.05% | 3.43% | 3.79% |
Operating Margin
-24.3%
Net Profit Margin
-24.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -23.50% |
| 2026-03-31 | -33.76% |
| 2025-12-31 | -14.57% |
| 2025-09-30 | -27.62% |
| 2025-06-30 | -31.97% |
| 2025-03-31 | -48.91% |
| 2024-12-31 | -63.08% |
| 2024-09-30 | -61.67% |
| 2024-06-30 | -91.03% |
| 2024-03-31 | -91.14% |
| 2023-12-31 | -137.92% |
| 2023-09-30 | -107.62% |
| 2023-06-30 | -143.83% |
| 2023-03-31 | -11.86% |
| 2022-12-31 | -251.28% |
| 2022-09-30 | -266.08% |
| 2022-06-30 | -469.82% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
